1. A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection
- Author
-
Singla, Amit, Dadario, Nicholas B, Singla, Ashima, Greenberg, Patricia, Yan, Rachel, Nanda, Anil, Boison, Detlev, Malhotra, Rakesh, Patel, Sunil, Nipun, Suri, Maninderpal, Kaur, Castro, Dorothy, Bdiiwi, Sanaa, Boktor, Hala, Kyi, Htay Htay, Sutherland, Anne, Patrawalla, Amee, Ly, Kevin, Xie, Yingda, Sonig, Ashish, Khandelwal, Priyank, Liu, James, Koziol, Joseph, Finkle, Diana, Subanna, Sara, and Libutti, Steven K
- Subjects
Lung ,Clinical Research ,Clinical Trials and Supportive Activities ,Prevention ,Infectious Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Female ,Humans ,COVID-19 ,Aspirin ,Dipyridamole Drug Combination ,SARS-CoV-2 ,Antiviral Agents ,Aspirin ,Treatment Outcome ,General Science & Technology - Abstract
BackgroundCoronavirus disease 2019 (COVID-19) is an immunoinflammatory and hypercoagulable state that contributes to respiratory distress, multi-organ dysfunction, and mortality. Dipyridamole, by increasing extracellular adenosine, has been postulated to be protective for COVID-19 patients through its immunosuppressive, anti-inflammatory, anti-coagulant, vasodilatory, and anti-viral actions. Likewise, low-dose aspirin has also demonstrated protective effects for COVID-19 patients. This study evaluated the effect of these two drugs formulated together as Aggrenox in hospitalized COVID-19 patients.MethodsIn an open-label, single site randomized controlled trial (RCT), hospitalized COVID-19 patients were assigned to adjunctive Aggrenox (Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally) with standard of care treatment compared to standard of care treatment alone. Primary endpoint was illness severity according to changes on the eight-point COVID ordinal scale, with levels of 1 to 8 where higher scores represent worse illness. Secondary endpoints included all-cause mortality and respiratory failure. Outcomes were measured through days 14, 28, and/or hospital discharge.ResultsFrom October 1, 2020 to April 30, 2021, a total of 98 patients, who had a median [IQR] age of 57 [47, 62] years and were 53.1% (n = 52) female, were randomized equally between study groups (n = 49 Aggrenox plus standard of care versus n = 49 standard of care alone). No clinically significant differences were found between those who received adjunctive Aggrenox and the control group in terms of illness severity (COVID ordinal scale) at days 14 and 28. The overall mortality through day 28 was 6.1% (3 patients, n = 49) in the Aggrenox group and 10.2% (5 patients, n = 49) in the control group (OR [95% CI]: 0.40 [0.04, 4.01], p = 0.44). Respiratory failure through day 28 occurred in 4 (8.3%, n = 48) patients in the Aggrenox group and 7 (14.6%, n = 48) patients in the standard of care group (OR [95% CI]: 0.21 [0.02, 2.56], p = 0.22). A larger decrease in the platelet count and blood glucose levels, and larger increase in creatinine and sodium levels within the first 7 days of hospital admission were each independent predictors of 28-day mortality (p < 0.05).ConclusionIn this study of hospitalized patients with COVID-19, while the outcomes of COVID illness severity, odds of mortality, and chance of respiratory failure were better in the Aggrenox group compared to standard of care alone, the data did not reach statistical significance to support the standard use of adjuvant Aggrenox in such patients.
- Published
- 2023